Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (224)	1/31/2006 2:22:28 PM
From: kenhott	Read Replies (1) \| Respond to of 588

That settles it then, you can certainly afford to give some poor guy (me) 12 bucks for a cup of coffee.

To: keokalani'nui who wrote (224)	1/31/2006 3:18:45 PM
From: scaram(o)uche	Respond to of 588

Irresponsible??...... well, everyone should have the "basket" concept put to them first, before having a third-tier biotech fetchingly thrown before them. Apart from that, it's one heck of a leveraged business plan with three projects of interest and (reputedly) a good preclinical lineup. Find me nine additional irresponsible recs, please.

To: keokalani'nui who wrote (224)	1/31/2006 3:35:14 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 588

basis for "2000"........ Message 22083377 I'm pleased that the stock has been brought to a wide audience. As top-tier market caps have gone thru roof, the cap delta between the strong currencies and the majority of pipe has gone wobbly irrational. Smallcap, big-science biotechs have PROVEN to be a great hangout, 1995 to present. There simply have never been better conditions for tiny bio, big-science. IMO, there are SEVERAL biotechs < $2B which should be promoted. The sector is a proven source of superior return.